|
| Author, publication year | Number of ablated patients | Median followup, months | Survival data | Comments |
|
|
Karabulut et al., 2011 [16] | 69
(RFA) | 22 | Median PFS: 10.5 months
Median OS: 73 months | No significant overall survival difference between RFA and resection |
|
|
Akyildiz et al., 2010 [23] | 89
(RFA; 78 with NETs of GI origin, 11 medullary thyroid cancer) | 30 | Median DFS: 15.6 months
Median OS: 72 months | Liver tumor volume (>76 cc versus <30 cc, ), symptoms (present versus absent, ), extrahepatic disease (present versus absent, ) |
|
|
Martin et al., 2010 [24] | 11
(MWA; 7 with concomitant hepatectomy; 6 with concomitant extrahepatic resection) | 36 | Median DFS: 8 months
Median OS: 18 months | Zero recurrences at ablation site |
|
|
Mazzaglia et al., 2007 [25] | 63
(RFA; 24 with extrahepatic disease at time of 1st ablation) | 34 | Median OS: 47 months after 1st RFA
5-year survival: 48% | Male gender (3x mortality risk of female) (),
largest tumor > 3 cm () |
|
|
Gillams and Lees, 2005 [26]
| 25
(RFA) | 21 (in 19 patients) | Median OS: 29 months | Shorter survival (23 months) in carcinoid patients |
|
|
Seifert et al., 1998 [27] | 13
(cryoablation) | 13.5 | 12 patients alive at the end of followup (up to 103 months) | All 7 symptomatic patients had subjective improvement |
|
|
Shapiro et al., 1998 [28] | 5
(cryoablation) | 30 | 1-year survival: 60%
2-year survival: 40% | All 5 patients had relief of carcinoid syndrome |
|
